GleamWall
中文EN

XLO Xilio Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1840233 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY73.0%
TTM net income YoY80.4%
TTM EPS YoY103.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-74.9%
Net margin-20.9%
FCF margin-104.8%
EBITDA margin-72.6%

Returns

ROE-38.2%
ROA-8.6%
ROIC (approx.)—
Asset turnover0.41x

Leverage & solvency

Liabilities / assets49.4%
Debt / equity0.00x
Current ratio4.72x
Interest coverage—

Cash quality & payout

Operating cash flow / net income4.95x
Accruals ratio33.8%
Payout ratio—
Capex / revenue1.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$43.77M$6.34M
R&D expense$56.04M$41.21M
SG&A expense$29.71M$24.78M
Operating income-$41.98M-$60.58M
Pretax income-$35.04M-$58.24M
Income tax$0$0
Net income-$35.04M-$58.24M
EBITDA-$40.44M-$58.94M
EPS (basic)-4.19-15.24
EPS (diluted)-4.19-15.24
Balance sheet
Cash & equivalents$137.53M$57.07M
Current assets$145.03M$60.23M
PP&E, net$3.89M$4.47M
Total assets$154.69M$71.08M
Current liabilities$56.27M$27.26M
Total liabilities$119.41M$53.48M
Shareholders' equity$35.27M$17.60M
Shares outstanding4.53M3.27M
Cash flow statement
Operating cash flow-$4.99M-$18.38M
Capital expenditure$518,000$36,000
Free cash flow-$5.51M-$18.41M
Investing cash flow-$518,000-$36,000
Financing cash flow$87.78M$29.20M
Depreciation & amortization$1.54M$1.64M
Stock-based compensation$6.94M$6.43M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.